Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease.
A trial was performed on thirty-two patients with cerebrovascular disease (transient ischaemic attack and stroke) to assess the effect of ticlopidine, a new inhibitor of platelet aggregation, on some platelet functions and coagulation, and its safety in long-term use (6 months). The results show that ticlopidine was highly effective in inhibiting ADP-induced platelet aggregation, platelet adhesiveness and circulating platelet aggregates, but it had no effect on fibrinogen levels. No serious side-effects were observed. Ticlopidine may therefore prove to be a useful antiplatelet drug in the management of patients with cerebrovascular disease.
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D013876:Thiophenes / Q000627:therapeutic use*; D013988:Ticlopidine; D013997:Time Factors
D000925:Anticoagulants; D013876:Thiophenes; D005340:Fibrinogen; D013988:Ticlopidine